Genomic and Imaging Study for Patients Undergoing Surgery for Liver Cancer

Status: Completed
Location: See location...
Intervention Type: Drug, Diagnostic Test
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This clinical trial studies positron emission tomography (PET)/computed tomography (CT) in diagnosing patients with liver cancer undergoing surgical resection. Diagnostic procedures, such as fluorine-18 fluoromethylcholine PET/CT, may help find and diagnose liver cancer.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: No
View:

• Liver tumor diagnosed histologically as HCC or suspected of being HCC in association with serum alpha-fetoprotein level > 200 or tumor mass with characteristics of malignancy on diagnostic imaging

• Under the care of a surgical attending

• Deemed a surgical candidate and has agreed to surgery to remove a portion of the liver containing tumor

• Child-Pugh A/B

Locations
United States
Hawaii
University of Hawaii Cancer Center
Honolulu
Time Frame
Start Date: August 15, 2011
Completion Date: May 31, 2018
Participants
Target number of participants: 64
Treatments
Experimental: 18F-fluoromethylcholine PET/CT
Patients undergo 18F-fluoromethylcholine positron emission tomography (PET)/ computed tomography (CT) scan within 14 days of surgical resection of liver tumor.
Authors
Related Therapeutic Areas
Sponsors
Leads: Queen's Medical Center
Collaborators: National Cancer Institute (NCI)

This content was sourced from clinicaltrials.gov

Similar Clinical Trials